Management of cutaneous T cell lymphoma: New and emerging targets and treatment options Journal Article


Authors: Li, J. Y.; Horwitz, S.; Moskowitz, A.; Myskowski, P. L.; Pulitzer, M.; Querfeld, C.
Article Title: Management of cutaneous T cell lymphoma: New and emerging targets and treatment options
Abstract: Cutaneous T cell lymphomas (CTCL) clinically and biologically represent a heterogeneous group of non-Hodgkin lymphomas, with mycosis fungoides and Sézary syndrome being the most common subtypes. Over the last decade, new immunological and molecular pathways have been identified that not only influence CTCL phenotype and growth, but also provide targets for therapies and prognostication. This review will focus on recent advances in the development of therapeutic agents, including bortezomib, the histone deacetylase inhibitors (vorinostat and romidepsin), and pralatrexate in CTCL. © 2012 Li et al, publisher and licensee Dove Medical Press Ltd.
Keywords: bortezomib; cutaneous t cell lymphoma; histone deacetylase inhibitors; pralatrexate; novel targets
Journal Title: Cancer Management and Research
Volume: 4
Issue: 1
ISSN: 1179-1322
Publisher: Dove Medical Press Ltd  
Date Published: 2012-01-01
Start Page: 75
End Page: 89
Language: English
DOI: 10.2147/cmar.s9660
PROVIDER: scopus
PMCID: PMC3308634
PUBMED: 22457602
DOI/URL:
Notes: --- - "Export Date: 1 May 2012" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Melissa P Pulitzer
    132 Pulitzer
  2. Steven M Horwitz
    382 Horwitz
  3. Alison Moskowitz
    161 Moskowitz
  4. Patricia Myskowski
    140 Myskowski